Literature DB >> 17576300

Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study.

Naoki Kimata1, Justin M Albert, Takashi Akiba, Shin Yamazaki, Takehiko Kawaguchi, Yoshindo Kawaguchi, Shunichi Fukuhara, Tadao Akizawa, Akira Saito, Yasushi Asano, Kiyoshi Kurokawa, Ronald L Pisoni, Friedrich K Port.   

Abstract

Abnormalities in mineral metabolism have been linked to mortality in hemodialysis (HD) patients. We postulated that these abnormalities would have a particularly large deleterious impact on deaths due to cardiovascular causes in Japan. This study describes the recent status of abnormal mineral metabolism, significant predictors, and potential consequences in the Dialysis Outcomes and Practice Patterns Study (DOPPS), Phases 1 and 2, in Japan. Major predictor variables were patient demographics, comorbidities, and laboratory markers of mineral metabolism such as albumin-adjusted serum calcium (calciumAlb), phosphorus, and intact PTH (iPTH). In a cross section of 3973 Japanese HD patients in DOPPS I and II, a large faction had laboratory values outside of the recommended Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline range for serum concentrations of phosphorus (51% of patients above upper target range), calciumAlb (43.7% above), calcium-phosphorus (Ca x P) product (41.1% above), and iPTH (18.6% above). All-cause mortality was significantly and independently associated with calciumAlb (relative risk [RR]=1.22 per 1 mg/dL, p=0.0005) and iPTH (RR=1.04 per 100 pg/mL, p=0.04). Cardiovascular mortality was significantly associated with calciumAlb (RR=1.28, p=0.02), phosphorus (RR=1.13 per 1 mg/dL, p=0.008), Ca x P product (RR=1.07 per 2 mg(2)/dL(2), p=0.002), and PTH (RR=1.08, p=0.0001). This study expands our understanding of the relationship between altered mineral metabolism and mortality outcomes, showing slightly stronger associations with cardiovascular causes than observed for all-cause mortality. These findings have important therapeutic implications for Japanese HD patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576300     DOI: 10.1111/j.1542-4758.2007.00190.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  43 in total

1.  Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.

Authors:  Tadao Akizawa; Ryo Kido; Masafumi Fukagawa; Yoshihiro Onishi; Takuhiro Yamaguchi; Takeshi Hasegawa; Shunichi Fukuhara; Kiyoshi Kurokawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 8.237

2.  Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD.

Authors:  Csaba P Kovesdy; Olga Kuchmak; Jun Ling Lu; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2010-08-21       Impact factor: 8.860

3.  Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.

Authors:  Bojan Kovacevic; Mile Ignjatovic; Vladan Zivaljevic; Vladimir Cuk; Milena Scepanovic; Zaklina Petrovic; Ivan Paunovic
Journal:  Langenbecks Arch Surg       Date:  2012-01-13       Impact factor: 3.445

4.  Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients.

Authors:  Fumihiko Koiwa; Daisuke Komukai; Makoto Hirose; Ashio Yoshimura; Ryoichi Ando; Toshifumi Sakaguchi; Yasuhiro Komatsu; Toshio Shinoda; Daijo Inaguma; Nobuhiko Joki; Hidemi Nishida; Masato Ikeda; Takashi Shigematsu
Journal:  Clin Exp Nephrol       Date:  2011-09-14       Impact factor: 2.801

5.  Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.

Authors:  Shunsuke Goto; Hirotaka Komaba; Kensuke Moriwaki; Akira Fujimori; Koji Shibuya; Masato Nishioka; Jong-Il Kim; Kunihiko Yoshiya; Jeongsoo Shin; Hirohito Hasegawa; Masatomo Taniguchi; Hideki Fujii; Shinichi Nishi; Isao Kamae; Masafumi Fukagawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-05       Impact factor: 8.237

6.  Prescribed dietary phosphate restriction and survival among hemodialysis patients.

Authors:  Katherine E Lynch; Rebecca Lynch; Gary C Curhan; Steven M Brunelli
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-09       Impact factor: 8.237

7.  Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease.

Authors:  Csaba P Kovesdy; Olga Kuchmak; Jun L Lu; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

8.  Relationship between parathyroid hormone and renin-angiotensin-aldosterone system in hemodialysis patients with secondary hyperparathyroidism.

Authors:  Keiji Kono; Hideki Fujii; Kentaro Watanabe; Shunsuke Goto; Shinichi Nishi
Journal:  J Bone Miner Metab       Date:  2020-09-12       Impact factor: 2.626

9.  The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients.

Authors:  Francesca Tentori; Lindsay Zepel; Douglas S Fuller; Mia Wang; Brian A Bieber; Bruce M Robinson; Ronald L Pisoni
Journal:  Am J Kidney Dis       Date:  2015-09       Impact factor: 8.860

Review 10.  Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.

Authors:  S N Salam; A Khwaja; M E Wilkie
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.